Organization (Other)
Arthrosi Therapeutics
ClinicalTrials.gov lists Arthrosi Therapeutics as lead sponsor of 10 trials. It has 21 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Arthrosi Therapeutics: 10 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (3)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Gout | 6 |
| Hyperuricemia | 6 |
| Arthritis, Gouty | 5 |
Trials by start year as sponsor or collaborator (6)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 2 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (21)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| AR882 75 mg | Hyperuricemia | Phase 3 | 3 |
| AR882 75 mg | Arthritis, Gouty | Phase 3 | 3 |
| AR882 75 mg | Gout | Phase 3 | 3 |
| AR882 50 mg | Gout | Phase 3 | 2 |
| AR882 50 mg | Arthritis, Gouty | Phase 3 | 2 |
Showing 5 of 21 active programs.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=6) | 17% on time (n=6) |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 5 | 3 | 2025-09-23 |
Financing and grant events (6)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-06-06 | Private placement | 60,869,972 | Form d |
| 2023-09-05 | Private placement | 7,000,000 | Form d |
| 2023-02-07 | Private placement | 15,000,000 | Form d |
| 2021-08-16 | Private placement | 26,000,000 | Form d |
| 2021-08-02 | Private placement | 220,000 | Form d |
Showing 5 of 6 events.
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Iqvia Holdings Inc. | Uses vendor | 1 |
Latest dated events (21)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-12-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-06-06 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-03-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-11-19 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 21 events.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, journals published in, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.